COMMENTARY A Physician's Guide to the Cannabidiol Craze Angela Coombs, MD; Diana M. Martinez, MD Medscape, May 31, 2019 Last month at the Columbia University Department of Psychiatry in upper Manhattan, Columbia chief psychiatry resident Dr Angela Coombs interviewed addiction expert Dr Diana Martinez on a number of issues related to the rising popularity and usage of cannabidiol (CBD). This transcript has been edited for clarity. Angela Coombs, MD: Hi. My name is Dr Angela Coombs and I'm a chief resident here at Columbia. We are so happy to be able to have Dr Diana Martinez, who's a professor in psychiatry at Columbia and an expert [...]
Lire la suiteA behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Leonora E. Long, Rose Chesworth, Xu-Feng Huang, Iain S. McGregor, Jonathon C. Arnold and Tim Karl International Journal of Neuropsychopharmacology, 2010, 13, 861–876. doi : 10.1017/S1461145709990605 Abstract Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9 tetrahydro-cannabinol (D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, [...]
Lire la suiteAre Your Patients Taking CBD? - Medscape - January 15, 2020 https://www.medscape.com/viewarticle/923801 Cannabidiol (CBD) is having its moment in the sun. A Gallup poll from last August found that 1 in 7 Americans use CBD, that 11% of users are 50 to 64 years of age, and that 8% are at least 65 years of age. Pain relief, anxiety, insomnia, and arthritis are the top reasons for use. Nearly 4 in 10 Americans think CBD oils should be legally available for adults to buy over the counter. Although the 2018 Farm Bill removed hemp (cannabis and cannabis derivatives such as CBD that contain less than 0.3% THC) [...]
Lire la suiteDrug-drug interactions as a result of coadministering Δ9-THC and CBD with other psychotropic agents Carola Rong, Nicole E. Carmona, Yena L. Lee, Renee-Marie Ragguett, Zihang Pan, Joshua D. Rosenblat, Mehala Subramaniapillai, Margarita Shekotikhina, Fahad Almatham, Asem Alageel, Rodrigo Mansur, Roger C. Ho & Roger S. McIntyre Expert Opinion on Drug Safety, 2018, 17:1, 51-54. Doi : 10.1080/14740338.2017.1397128 ABSTRACT Introduction : To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways would be predicted to result in clinically significant drug-drug interactions (DDIs) with commonly prescribed psychotropic agents. Areas covered: A non-systematic literature search was conducted using the following [...]
Lire la suiteThe Role of Cannabis in Treating Anxiety : An Update Michael Van Ameringen; Jasmine Zhang; Beth Patterson; Jasmine Turna Current Opinion in Psychiatry, 2019, 33, (1), 1-7. DOI : 10.1097/YCO.0000000000000566 https://www.medscape.com/viewarticle/922111?nlid=133169_425&src=WNL_mdplsfeat_191224_mscpedit_psyc&uac=292598PZ&spon=12&impID=2219742&faf=1 Abstract and Introduction Abstract Purpose of review: Cannabis use for medical purposes has become increasingly common, including as treatment for mental health disorders such as anxiety. Unfortunately, the evidence examining its use in mental health has been slow to evolve, but is emerging. Given the widespread use of cannabis, it is important for both clinicians and those who suffer with anxiety to understand the effects of cannabis on symptoms of anxiety. In this review, we present [...]
Lire la suiteReal-World Approaches to Cannabinoids in Pediatric-Onset Epilepsy: What Do the Data Tell Us? CME Anup Patel, MD Posted: 12/19/2019 https://www.medscape.org/viewarticle/922715 Educational Impact Challenge The goal of this activity is to improve knowledge and competence related to the selection of cannabinoid-based therapies for pediatric-onset seizure disorders. Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers. What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your [...]
Lire la suiteCannabis thérapeutique : l’Assemblée autorise une expérimentation Pierre Dharréville. LIBERATION, Avec AFP — 25 octobre 2019 à 09:26 (mis à jour à 10:08) https://www.liberation.fr/france/2019/10/25/cannabis-therapeutique-l-assemblee-autorise-une-experimentation_1759658 Cette expérimentation concernera des personnes souffrant de maladies graves pour lesquelles les dérivés du cannabis peuvent constituer un apport thérapeutique supplémentaire. C’est «oui». L’Assemblée nationale a donné vendredi son feu vert à une expérimentation de l’usage médical du cannabis, dans le cadre de l’examen du projet de budget de la Sécurité sociale pour 2020. Les députés ont voté à main levée un amendement du rapporteur Olivier Véran (LREM) qui autorise pour deux ans [...]
Lire la suiteProcès de Kanavape : Sébastien Béguerie la joue chanvre idéal Par Samantha Rouchard, correspondance à Marseille, — 22 octobre 2019 à 19:46 https://www.liberation.fr/france/2019/10/22/proces-de-kanavape-sebastien-beguerie-la-joue-chanvre-ideal_1759122 Après plus de quatre ans de feuilleton et une condamnation, la Cour de justice de l’UE se penche ce mercredi sur la vape au CBD conçue par le Marseillais, qui vante ses vertus relaxantes. La décision pourrait faire jurisprudence pour les dérivés de cannabis «light». «En lançant Kanavape, on se doutait qu’on allait faire un buzz mais pas de cette envergure !» Le Marseillais Sébastien Béguerie est l’inventeur de la première cigarette électronique au cannabidiol (CBD), molécule du cannabis dite relaxante, au statut juridique toujours indéterminé en France. Son lancement [...]
Lire la suiteCannabis CBD : un an après, où en est-on ? Par Service Checknews 4 juillet 2019 à 17:42 Si la loi française se veut claire en matière de commercialisation de produits issus du cannabis, un flou persiste dans la pratique autour du cannabidiol. Question posée par Nicolas le 28/06/2019 Bonjour, Vous nous avez posé cette question : «Est-ce que le commerce de la fleur de CBD est autorisé en France ? Quelles sont les règles à respecter ?» Vous faites référence au CBD (cannabidiol), une molécule de chanvre contenue dans la plante de cannabis au même titre que le THC (tétrahydrocannabinol). A [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suite